ONO-2020
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
ONO-2020 is an epigenetic modulator, immunomodulator, and possible cognitive enhancer which is under development for the treatment of agitation including due to Alzheimer's disease. It is taken orally. The drug's exact mechanism of action or biological target does not yet appear to have been disclosed. ONO-2020 is under development by Ono Pharmaceutical. As of May 2025, it is in phase 2 clinical trials for treatment of agitation and Alzheimer's disease. The chemical structure of ONO-2020 does not yet appear to have been disclosed.
ONO-2020 is an epigenetic modulator, immunomodulator, and possible cognitive enhancer which is under development for the treatment of agitation including due to Alzheimer's disease. It is taken orally. The drug's exact mechanism of action or biological target does not yet appear to have been disclosed. ONO-2020 is under development by Ono Pharmaceutical. As of May 2025, it is in phase 2 clinical trials for treatment of agitation and Alzheimer's disease. The chemical structure of ONO-2020 does not yet appear to have been disclosed.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1368787505 under CC BY-SA 4.0; modifications have been made.